NeuroMetrix Rceives GSK 'Bridge' For Quell Wearable Pain-Relief Development
Executive Summary
Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.